{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:53:36Z","timestamp":1786334016020,"version":"build-2736575974"},"reference-count":120,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","award":["DNRF126"],"award-info":[{"award-number":["DNRF126"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","award":["C20\/BM\/14592342"],"award-info":[{"award-number":["C20\/BM\/14592342"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.02.001","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:43:42Z","timestamp":1676051022000},"page":"322-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management"],"prefix":"10.1016","volume":"23","author":[{"given":"Ernesto","family":"Gargiulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Flavio Oliveira","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0001","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41375-020-0980-0","article-title":"Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study","volume":"35","author":"Andersen","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0002","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.17857","article-title":"Chronic lymphocytic leukaemia clones are detectable decades before diagnosis","volume":"196","author":"Vojdeman","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0003","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0004","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41375-018-0316-5","article-title":"Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study","volume":"33","author":"Andersen","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological malignancies: results from a nationwide 16-year cohort study","volume":"72","author":"Andersen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0007","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2023.02.001_bib0008","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13756-022-01067-1","article-title":"Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values","volume":"11","author":"Thornton","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"issue":"23","key":"10.1016\/j.clml.2023.02.001_bib0010","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0011","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy","volume":"222","author":"Helleberg","year":"2020","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0012","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/jiab249","volume":"224","author":"Helleberg","year":"2021","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.clml.2023.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/s41375-020-0941-7","article-title":"COVID-19 among fit patients with CLL treated with venetoclax-based combinations","volume":"34","author":"F\u00fcrstenau","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0014","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0015","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0016","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2023.02.001_bib0017","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-12-471698","article-title":"Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL","volume":"121","author":"Vardi","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0018","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0019","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder Jr","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death","volume":"57","author":"Andersen","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.clml.2023.02.001_bib0021","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0022","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.","article-title":"Infectious complications in chronic lymphocytic leukemia","volume":"4","author":"Nosari","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12032-007-9037-8","article-title":"Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia","volume":"25","author":"Alexandrescu","year":"2008","journal-title":"Med Oncol"},{"issue":"25","key":"10.1016\/j.clml.2023.02.001_bib0024","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0025","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1080\/10428190400007763","article-title":"Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status","volume":"45","author":"Sinisalo","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0026","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0027","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2008.07050.x","article-title":"Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait","volume":"141","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.02.001_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0030","first-page":"1509","article-title":"The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives","volume":"10","author":"Schlesinger","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0031","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2249.1991.tb05655.x","article-title":"Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia","volume":"83","author":"Tooze","year":"1991","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0032","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2141.1992.tb06431.x","article-title":"Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies","volume":"82","author":"Hara","year":"1992","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.02.001_bib0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.1992.tb04561.x","article-title":"B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta","volume":"80","author":"Kremer","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.02.001_bib0034","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1749-6632.1991.tb17267.x","article-title":"Transforming growth factor-beta is a potent negative regulator of human lymphocytes","volume":"628","author":"Kehrl","year":"1991","journal-title":"Ann N Y Acad Sci"},{"issue":"15","key":"10.1016\/j.clml.2023.02.001_bib0035","first-page":"4497","article-title":"The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response","volume":"63","author":"Orsini","year":"2003","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.clml.2023.02.001_bib0036","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 Is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0038","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V70.2.396.396","article-title":"High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia","volume":"70","author":"Semenzato","year":"1987","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0039","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2643-3230.BCD-22-0029","article-title":"Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses","volume":"4","author":"Gargiulo","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0040","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO;2-Y","article-title":"Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22","volume":"32","author":"Ghia","year":"2002","journal-title":"Eur J Immunol"},{"issue":"13","key":"10.1016\/j.clml.2023.02.001_bib0041","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0042","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.02.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108326","article-title":"Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease","volume":"9","author":"Huergo-Zapico","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0044","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12967-018-1545-0","article-title":"Immunosuppressive treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients","volume":"16","author":"De Matteis","year":"2018","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0046","first-page":"1128","article-title":"Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: a one year follow-up","volume":"30","author":"Tang","year":"2014","journal-title":"Pak J Med Sci"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0047","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-016-1921-7","article-title":"Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs)","volume":"66","author":"Podaza","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"10.1016\/j.clml.2023.02.001_bib0048","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1158\/0008-5472.CAN-15-3486","article-title":"Splenic marginal zone granulocytes acquire an accentuated neutrophil B-Cell helper phenotype in chronic lymphocytic leukemia","volume":"76","author":"Gatjen","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0049","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0609.1996.tb00489.x","article-title":"Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia","volume":"57","author":"Itala","year":"1996","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2023.02.001_bib0050","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.001_bib0051","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/cddiscovery.2016.20","article-title":"Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling","volume":"2","author":"van Attekum","year":"2016","journal-title":"Cell Death Discov"},{"issue":"3-4","key":"10.1016\/j.clml.2023.02.001_bib0052","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2119\/molmed.2009.00146","article-title":"CD38\/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells","volume":"16","author":"Deaglio","year":"2010","journal-title":"Mol Med"},{"issue":"11","key":"10.1016\/j.clml.2023.02.001_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines8110516","article-title":"Macrophage polarization in chronic lymphocytic leukemia: nurse-like cells are the caretakers of leukemic cells","volume":"8","author":"Mesaros","year":"2020","journal-title":"Biomedicines"},{"issue":"13","key":"10.1016\/j.clml.2023.02.001_bib0054","doi-asserted-by":"crossref","first-page":"eaah5509","DOI":"10.1126\/sciimmunol.aah5509","article-title":"Tumor-derived exosomes modulate PD-L1 expression in monocytes","volume":"2","author":"Haderk","year":"2017","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0055","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2023.02.001_bib0056","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2023.02.001_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK Inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"issue":"10232","key":"10.1016\/j.clml.2023.02.001_bib0058","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2023.02.001_bib0059","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.02.001_bib0061","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0062","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0063","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0064","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","article-title":"Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia","volume":"5","author":"Mulder","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.clml.2023.02.001_bib0065","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T Cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0066","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0067","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.clml.2023.02.001_bib0068","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0069","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0070","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0071","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in relapsed or refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.02.001_bib0072","unstructured":"TIME-limited venetoclax-obinutuzumab +\/- ibrutinib is superior to.... eha library. eichhorst B. 2022; 366209. Available at: https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/366209\/barbara.eichhorst.time-limited.venetoclax-obinutuzumab.2B.-.ibrutinib.is.html.Accessed November 12, 2022"},{"issue":"16","key":"10.1016\/j.clml.2023.02.001_bib0073","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2023.02.001_bib0074","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/cancers13061280","article-title":"Challenges and future therapeutic opportunities for PI3K inhibition in CLL","volume":"13","author":"Guarente","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.02.001_bib0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fimmu.2012.00224","article-title":"The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions","volume":"3","author":"Pauls","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.02.001_bib0076","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nyas.12027","article-title":"Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity","volume":"1280","author":"Okkenhaug","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"7629","key":"10.1016\/j.clml.2023.02.001_bib0077","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0078","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1164\/rccm.200610-1533OC","article-title":"Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection","volume":"175","author":"Maus","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5455","key":"10.1016\/j.clml.2023.02.001_bib0079","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science (80-)"},{"issue":"11","key":"10.1016\/j.clml.2023.02.001_bib0080","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.02.001_bib0081","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.02.001_bib0082","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0083","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0084","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.clml.2023.02.001_bib0085","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2023.02.001_bib0086","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.02.001_bib0087","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2796.2000.00730.x","article-title":"Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia","volume":"248","author":"Krebs","year":"2000","journal-title":"J Intern Med"},{"issue":"26","key":"10.1016\/j.clml.2023.02.001_bib0088","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0089","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2023.02.001_bib0090","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_bib0091","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rmv.710","article-title":"Progressive multifocal leukoencephalopathy: clinical and molecular aspects","volume":"22","author":"Tavazzi","year":"2012","journal-title":"Rev Med Virol"},{"issue":"8","key":"10.1016\/j.clml.2023.02.001_bib0092","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2011-03-341032","article-title":"Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2023.02.001_bib0093","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.02.001_bib0094","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.clml.2023.02.001_bib0095","unstructured":"NCCN Guideline for prevention and treatment of Cancer related infection. Version 3.2022 ..\u00f7 October 28, 2022. NCCN.org."},{"key":"10.1016\/j.clml.2023.02.001_bib0096","unstructured":"CDC- Recommended adult immunization schedule, United States 2022. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html."},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0097","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0098","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0099","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2023.02.001_bib0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.18075","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia","volume":"197","author":"Walewska","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0101","first-page":"121","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Kumar Rao","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clml.2023.02.001_bib0102","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1345\/aph.1A434","article-title":"Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients","volume":"36","author":"Warkentin","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.clml.2023.02.001_bib0104","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/1078155219875507","article-title":"Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors","volume":"26","author":"Laali","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.clml.2023.02.001_bib0106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","article-title":"Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"13","author":"Waggoner","year":"2022","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.001_bib0107","first-page":"2563","article-title":"The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial","volume":"35","author":"Else","year":"2021","journal-title":"Leuk 2021 359"},{"issue":"12","key":"10.1016\/j.clml.2023.02.001_bib0108","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/bloodadvances.2021006351","article-title":"Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data","volume":"6","author":"Parviz","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.02.001_bib0109","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2019-121907","volume":"134","author":"Da Cunha-Bang","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.02.001_bib0111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0112","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.02.001_bib0113","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the Phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.02.001_bib0114","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2023.02.001_bib0115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clml.2023.02.001_bib0116","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMc1309710","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Neffendorf","year":"2013","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.clml.2023.02.001_bib0117","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2023.02.001_bib0118","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.001_sbref0119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.02.001_bib0120","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:42Z","timestamp":1761871362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000368"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}